CanAg® Glypican-3 EIA

About Biomosaics

BioMosaics is a private, revenue-generating diagnostics company focused on the Glypican-3 (GPC3) biomarker for liver cancer. The company commercializes a suite of validated antibodies and immunoassays, including its CanAg® EIA, primarily for research and clinical diagnostic use. With a leadership team experienced in biotechnology and academic research, and key scientific partnerships, BioMosaics positions itself as a quality provider in the niche GPC3 diagnostics space. The company's products support the broader therapeutic development landscape targeting GPC3 in oncology.

Therapeutic Areas